Sign in
Taking people in United KingdomPhase 4

Tests an inhaler against a placebo inhaler in people with COPD and hyperinflation

Compares a combination inhaler with a placebo inhaler for heart and lung function in COPD.

Key facts

Who runs it
AstraZeneca
Where
Harefield, London, and Manchester, United KingdomSee the 3 sitesAlso in 1 other country, 4 sites
Registry title
A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation
Status
Recruiting
Phase
Phase 4
People taking part
56 people, planned
Started
24 Nov 2025
Expected to end
31 May 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Budesonide/Glycopyrronium/Formoterol Fumarate
  • Placebo
  • Metered dose inhaler
Record updated
18 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40 to 80 with COPD and lung hyperinflation who are current or former smokers and already use inhaled COPD maintenance treatment.

Age
40 to 80 years
Sex
Women and men can join.
Disease stage
COPD confirmed by FEV1/FVC < 0.7, with pre-bronchodilator FEV1 < 80% at Visit 1, post-bronchodilator FEV1 of at least 30% and under 80% at Visit 2, mMRC of 1 or more, and hyperinflation (FRC > 135% of predicted normal).
Earlier treatment
Must be on mono-, dual-, or triple-inhaled maintenance COPD treatment.
Biomarker or test result
Blood eosinophil count < 300 cells/mm³ at Visit 1, with no eosinophil count > 300 cells/mm³ in the past 12 months.

Main reasons for not taking part

  • Current asthma, asthma-COPD overlap, or another chronic lung disease besides COPD
  • COPD flare needing hospital stay, or 2 or more needing systemic corticosteroids
  • Past heart attack or acute coronary syndrome
  • Serious heart rhythm problem, or a pacemaker or similar implanted heart device
  • Lung infection within 8 weeks before Visit 1, or lung surgery such as lobectomy or lung volume reduction

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Current or former smoker with a history of ≥ 10 pack-years of tobacco smoking
  • A diagnosis of COPD confirmed by a post-bronchodilator forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) < 0.7
  • At Visit 1: A pre-bronchodilator FEV1 < 80%
  • At Visit 1: Peripheral blood eosinophil count < 300 cells/cubic millimeter (mm³), with no recorded history of eosinophil count > 300 cells/mm³ in the past 12 months
  • At Visit 1: Modified Medical Research Council (mMRC) ≥ 1
  • At Visit 2: A pre-bronchodilator functional residual capacity (FRC) of > 135% of predicted normal FRC
  • At Visit 2: A post-bronchodilator FEV1 ≥ 30% and < 80% of the predicted normal value
  • Participants must be on mono-, dual-, or triple-inhaled maintenance COPD treatment
  • Female participants must either be not of childbearing potential or using a form of highly effective birth control
  • All women of child bearing potential must have a negative pregnancy test at the Visit 1

Who cannot take part

  • Participants who have had a respiratory tract infection within 8 weeks prior to Visit 1 and/or during the screening/run-in period
  • Participants with lung lobectomy, lung volume reduction (during the study and within 3 months of Visit 1), or lung transplantation
  • A current diagnosis of asthma, asthma-COPD overlap, or any other chronic respiratory disease other than COPD, such as alpha-1 antitrypsin deficiency, active tuberculosis, lung cancer, lung fibrosis, sarcoidosis, interstitial lung disease, and pulmonary hypertension
  • History of a COPD exacerbation that required hospitalisation, or 2 or more COPD exacerbations that required systemic corticosteroids
  • History of myocardial infarction or acute coronary syndrome
  • History or current clinically significant atrial or ventricular arrhythmia to be confirmed by electrocardiogram (ECG)
  • Participants with a cardiac implantable electronic device, including pacemaker, implantable cardioverter defibrillator, or cardiac resynchronization therapy
  • Participants with ECG QTcF interval at Visit 1 > 460 milliseconds (ms) for males and > 480 ms for females

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 80 years old?

Where in United Kingdom

Also in 1 other country, 4 sites

  • HarefieldHospital not named in the registryNo longer taking part
  • LondonHospital not named in the registryTaking people
  • ManchesterHospital not named in the registryTaking people

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the effect of BGF MDI compared with placebo MDI on cardiac and lung function when administered in participants diagnosed with COPD and hyperinflation.

The 2 groups in the trial

  • Sequence 1: BGF MDI and PlaceboTreatment being tested

    Participants will receive BGF MDI in Period 1 followed by Placebo in Period 2.

    Treatment: Budesonide/Glycopyrronium/Formoterol Fumarate, Placebo, and Metered dose inhaler

  • Sequence 2: Placebo and BGF MDITreatment being tested

    Participants will receive Placebo in Period 1 followed by BGF MDI in Period 2.

    Treatment: Budesonide/Glycopyrronium/Formoterol Fumarate, Placebo, and Metered dose inhaler

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With Chronic Obstructive Pulmonary Disease and Hyperinflation
Plain-language title
Tests an inhaler against a placebo inhaler in people with COPD and hyperinflationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07073950, who can take part
Record updated
18 September 2026